Estimation of Annual Health Care Costs for Adults with Type 1 Diabetes in the United States

Joish, Vijay N.; Zhou, Fang Liz; Preblick, Ronald; Lin, Dee; Deshpande, Maithili; Verma, Sumit; Davies, Melanie J.; Paranjape, Sachin A.; Pettus, Jeremy

doi:10.18553/jmcp.2020.26.3.311

Cited by 11 publications

(9 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because the onset of T1DM typically arises early, effective disease management is imperative to limit its health and economic impact [14]. Existing literature has highlighted the higher cost of treating T1DM compared with T2DM [15]. To understand the economic impact of T1DM, the IQVIA CDM is used to evaluate the health care resource utilization over a 12-month period in patients with controlled and uncontrolled T1DM in the public health care sector.…”

Section: Discussionmentioning

confidence: 99%

“…In the base-case analyses, second-order uncertainty is not applied, and stability of outcomes is reached through a run of 1000 patients through 1000 iterations. There is an existing and emerging body of evidence looking to quantify health care resource utilization and appropriately describe economic considerations in the management of people living with T1DM [14,15]. There is, however, a lack of such data within developing nations that are required to facilitate policy discussions pertaining to the health and economic impact of T1DM in South Africa.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Health Care Resource Utilization in Adults Living With Type 1 Diabetes Mellitus in the South African Public Health Sector: Protocol for a 1-Year Retrospective Analysis With a 5-, 10-, and 25-Year Projection

Bhana¹,

Naidoo²,

Pillay³

et al. 2023

JMIR Res Protoc

View full text Add to dashboard Cite

Background Type 1 diabetes mellitus (T1DM) is less common than type 2 diabetes mellitus but is increasing in frequency in South Africa. It tends to affect younger individuals, and upon diagnosis, exogenous insulin is essential for survival. In South Africa, the health care system is divided into private and public health care systems. The private system is well resourced, whereas the public sector, which treats more than 80% of the population, has minimal resources. There are currently no studies in South Africa, and Africa at large, that have evaluated the immediate and long-term costs of managing people living with T1DM in the public sector. Objective The primary objective was to quantify the cost of health care resource utilization over a 12-month period in patients with controlled and uncontrolled T1DM in the public health care sector. In addition, we will project costs for 5, 10, and 25 years and determine if there are cost differences in managing subsets of patients who achieve glycemic control (hemoglobin A1c [HbA1c] <7%) and those who do not. Methods The study was performed in accordance with Good Epidemiological Practice. Ethical clearance and institutional permissions were acquired. Clinical data were collected from 2 tertiary hospitals in South Africa. Patients with T1DM, who provided written informed consent, and who satisfied the inclusion criteria were enrolled in the study. Data collection included demographic and clinical characteristics, acute and chronic complications, hospital admissions, and so on. We plan to perform a cost-effectiveness analysis to quantify the costs of health care utilization in the preceding 12 months. In addition, we will estimate projected costs over the next 10 years, assuming that study participants maintain their current HbA1c level. The cost-effectiveness analysis will be modeled using the IQVIA CORE Diabetes Model. The primary outcome measures are incremental quality-adjusted life years, incremental costs, incremental cost-effectiveness ratios, and incremental life years. Results Ethical clearance and institutional approval were obtained (reference number 200407). Enrollment began on February 9, 2021, and was completed on August 24, 2021, with 224 participants. A database lock was performed on October 29, 2021. The statistical analysis and clinical study report were completed in January 2022. Conclusions At present, there are no data assessing the short- and long-term costs of managing patients with T1DM in the South African public sector. It is hoped that the findings of this study will help policy makers optimally use limited resources to reduce morbidity and mortality in people living with T1DM. International Registered Report Identifier (IRRID) RR1-10.2196/44308

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Health Care Resource Utilization in Adults Living With Type 1 Diabetes Mellitus in the South African Public Health Sector: Protocol for a 1-Year Retrospective Analysis With a 5-, 10-, and 25-Year Projection

Bhana¹,

Naidoo²,

Pillay³

et al. 2023

JMIR Res Protoc

View full text Add to dashboard Cite

show abstract

“…Very recently, Heald et al reported that type 1 diabetes results in an average of 7.6 years of life lost [2], whilst Livingstone et al reported that it is associated with approximately 11 years of life lost for men and 13 years for women [3]. Type 1 diabetes also has significant societal costs, including loss of work days [1] and health care related costs [4].…”

Section: Introductionmentioning

confidence: 99%

Maternal and Childhood Diet and Human Type 1 Diabetes Risk

Abela

Fava

2022

J Endocrinol Metab

View full text Add to dashboard Cite

Background:The incidence of type 1 diabetes is increasing worldwide for reasons which are incompletely understood. The objective of the study was to investigate the potential association of maternal and childhood dietary components to type 1 diabetes in a case-control retrospective study.Methods: Data of diet during pregnancy and during childhood before the diagnosis of type 1 diabetes were gathered using a modified food frequency questionnaire in 88 mothers of type 1 diabetes patients and 88 mothers of controls. Children born on the same day and of the same sex of type 1 diabetes patients were chosen as controls.Results: Consumption of savoury cakes, savoury pies and ice-cream was significantly more frequent in mothers of type 1 diabetic subjects than in mothers of controls in univariate, but not in multivariate, analysis. Children with type 1 diabetes consumed bread and fish more frequently, and chicken less frequently before diagnosis when compared to controls. There were no differences in the frequency of intake of milk, sweet drinks and tea, fruit, dried fruit, vegetables, potatoes, uncooked cereal, rice or pasta, pizza, savoury cakes and pies, biscuits, packaged snacks, cakes, candy or chocolate. Consumption of bread was independently associated with increased risk of type 1 diabetes whilst consumption of chicken was independently associated with decreased risk in multivariate analysis. Conclusion:We support the hypothesis that dietary factors may be implicated in the pathogenesis of type 1 diabetes.

show abstract

“…The current COVID-19 pandemic has additionally highlighted that diabetes is a major risk factor for severe bouts of disease (7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18). In particular, type 1 diabetes (T1D) is a significant burden that typically appears during adolescence and requires life-long insulin administration and blood glucose monitoring (19). T1D is a chronic disease characterized by the autoimmune destruction of pancreatic islet b cells (20).…”

Section: Introductionmentioning

confidence: 99%

Immune Protection of Stem Cell-Derived Islet Cell Therapy for Treating Diabetes

Tahbaz

Yoshihara

2021

Front. Endocrinol.

View full text Add to dashboard Cite

Insulin injection is currently the main therapy for type 1 diabetes (T1D) or late stage of severe type 2 diabetes (T2D). Human pancreatic islet transplantation confers a significant improvement in glycemic control and prevents life-threatening severe hypoglycemia in T1D patients. However, the shortage of cadaveric human islets limits their therapeutic potential. In addition, chronic immunosuppression, which is required to avoid rejection of transplanted islets, is associated with severe complications, such as an increased risk of malignancies and infections. Thus, there is a significant need for novel approaches to the large-scale generation of functional human islets protected from autoimmune rejection in order to ensure durable graft acceptance without immunosuppression. An important step in addressing this need is to strengthen our understanding of transplant immune tolerance mechanisms for both graft rejection and autoimmune rejection. Engineering of functional human pancreatic islets that can avoid attacks from host immune cells would provide an alternative safe resource for transplantation therapy. Human pluripotent stem cells (hPSCs) offer a potentially limitless supply of cells because of their self-renewal ability and pluripotency. Therefore, studying immune tolerance induction in hPSC-derived human pancreatic islets will directly contribute toward the goal of generating a functional cure for insulin-dependent diabetes. In this review, we will discuss the current progress in the immune protection of stem cell-derived islet cell therapy for treating diabetes.

show abstract

Estimation of Annual Health Care Costs for Adults with Type 1 Diabetes in the United States

Cited by 11 publications

References 19 publications

Health Care Resource Utilization in Adults Living With Type 1 Diabetes Mellitus in the South African Public Health Sector: Protocol for a 1-Year Retrospective Analysis With a 5-, 10-, and 25-Year Projection

Health Care Resource Utilization in Adults Living With Type 1 Diabetes Mellitus in the South African Public Health Sector: Protocol for a 1-Year Retrospective Analysis With a 5-, 10-, and 25-Year Projection

Maternal and Childhood Diet and Human Type 1 Diabetes Risk

Immune Protection of Stem Cell-Derived Islet Cell Therapy for Treating Diabetes

Contact Info

Product

Resources

About